Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.62 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL507782 | 0.84 | NOTUM (0.72) | NPC1HTTRAB9ASMN1; SMN2SIRT2 | |
| SCHEMBL201423 | 0.82 | NOTUM (0.56) | NPC1HTTRAB9ASMN1; SMN2SIRT2 | |
| SCHEMBL26232436 | 0.82 | NPC1 (0.73) | NPC1HTTRAB9ASMN1; SMN2SIRT2 | |
| SCHEMBL26009685 | 0.82 | NOTUM (0.56) | NPC1HTTRAB9ASMN1; SMN2SIRT2 | |
| SCHEMBL14948949 | 0.82 | NOTUM (0.70) | NPC1HTTRAB9ASMN1; SMN2SIRT2 | |
| SCHEMBL12617891 | 0.82 | NOTUM (0.64) | NPC1RAB9ASMN1; SMN2NOTUMMAPT | |
| SCHEMBL28912728 | 0.82 | SIRT2 (0.71) | NPC1HTTRAB9ASMN1; SMN2SIRT2 | |
| SCHEMBL10937283 | 0.82 | SIRT2 (0.71) | NPC1HTTRAB9ASMN1; SMN2SIRT2 | |
| SCHEMBL10904042 | 0.82 | SMN1; SMN2 (0.59) | NPC1HTTRAB9ASMN1; SMN2MAPT | |
| SCHEMBL25916014 | 0.82 | NOTUM (0.51) | NPC1HTTRAB9ASMN1; SMN2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115093377-B | Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof | 贵州大学 | 2023-04-07 | — | — | CN | claimed |
| CN-115093377-A | Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof | 贵州大学 | 2022-09-23 | — | — | CN | claimed |
| US-20250223278-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-12240831-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-12012395-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-11970470-B1 | {5-chloro-2-(2-(3-(substitutedphenyl)-1,2,4-oxadiazol-5-yl)ethyl)phenyl}(phenyl)methanones as larvicidal agents | King Faisal University (SA) | 2024-04-30 | — | — | US | disclosed |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11873290-B2 | — | — | 2024-01-16 | — | — | US | disclosed |
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2009139709-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2009-08-20 | — | — | US | disclosed |
| WO-2009094028-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009061924-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | AMYGDALA NEUROSCIENCES, INC. | 2009-05-14 | — | — | US | disclosed |
| EP-2046769-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080207610-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2008014497-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | CREBBP, CREB1, EP300 | NPC1 1730/4885HTT 2537/4885RAB9A 2899/4885 |
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | NPC1 4135/4885HTT 2529/4885RAB9A 2744/4885 |
| US-12012395-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | NPC1 4205/4885HTT 3021/4885RAB9A 3148/4885 |
| US-20080207610-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | NPC1 2592/4885HTT 3807/4885RAB9A 2946/4885 |
| US-12240831-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | NPC1 4205/4885HTT 3021/4885RAB9A 3148/4885 |
| US-11970470-B1 | {5-chloro-2-(2-(3-(substitutedphenyl)-1,2,4-oxadiazol-5-yl)ethyl)phenyl}(phenyl)methanones as larvicidal agents | CASP3, CASP2, CASP7 | NPC1 1200/4885HTT 4304/4885RAB9A 3675/4885 |
| US-11873290-B2 | — | IL6, MUSK, IL6ST | NPC1 4167/4885HTT 2657/4885RAB9A 3240/4885 |
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | NPC1 2592/4885HTT 3807/4885RAB9A 2946/4885 |
| US-20250223278-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | NPC1 4205/4885HTT 3021/4885RAB9A 3148/4885 |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | NPC1 2682/4885HTT 3853/4885RAB9A 2475/4885 |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | ALDH2, ALDH1A2, ALDH1A1 | NPC1 1978/4885HTT 3900/4885RAB9A 2092/4885 |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | NPC1 4205/4885HTT 3021/4885RAB9A 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.